Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TranspoCART19 in refractory or resistant CD19+ acute lymphoblastic leukemia
2025-522673-11-00Phase 2Authorised
- Sponsor
- Clínica Universidad de Navarra
- Start
- Jan 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TranspoCART19 in acute lymphoblastic leukemia (ALL), sponsored by Clínica Universidad de Navarra. Primary endpoints: Maximum tolerated dose and safety of TranspoCART19 and Efficacy of TranspoCART19 infusion. Planned start Jan 2026; status: authorised.
02
Drugs
TranspoCART19
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2025-522673-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522673-11-00.